within Pharmacolibrary.Drugs.ATC.M;

model M03AC08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.1666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00011999999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00016,
    k12             = 0.18,
    k21             = 0.18
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M03AC08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fazadinium bromide is a non-depolarizing neuromuscular blocking agent that was used to induce muscle relaxation during surgical procedures or mechanical ventilation. It acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction. The drug is no longer widely used or approved in most countries due to the development of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adult individuals based on typical ranges for similar non-depolarizing neuromuscular blocking agents; no direct pharmacokinetic publications or sources found.</p><h4>References</h4><ol><li><p>Pastorino, AM (1978). Fluorimetric determination and pharmacokinetic studies of fazadinium bromide in dogs. <i>Arzneimittel-Forschung</i> 28(10) 1728–1730. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39568/&quot;>https://pubmed.ncbi.nlm.nih.gov/39568</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M03AC08;
